Photo - QUINTAMED
53697

QUINTAMED

Pharmaceutical business

Ukraine, Kharkov region
Market: Medicine, Pharmacology
Stage of the project: Operating business

Date of last change: 09.11.2021
Sale price
$  1.200.000
Show contacts
3
share to sell
49%
Rating
equalizer from 1000
help
Calculated and estimated occupancy of the project (more about ratings)
My rating
1
2
3
4
5
6
7
8
9
10
Average rating:
 

Does the enterprise work?

Yes

Idea

Development, marketing and sales of pharmaceutical products.

Current Status

The company is 5 years old. 2 legal entities (Ukraine / Estonia).
The company is at the stage of scaling. Sales: 2nd year ~ 20,000 USD, 3rd year ~ 100,000 USD, 4th year ~ 300,000 USD.
The planned increase of the company's value from 2022 to 2030 is 7-14 times.
The planned amount of dividends is 11-25% per annum.

Annual sales, $

300000

Annual net income, $

42000

Property and assets

Tangible assets:
goods,
raw materials,
electronic and office devices.
Intangible assets:
trademarks,
technical documentation,
web-sites and social media

Organizational form

LLC

Number of employees

9

Problem or Opportunity

For each our product there is a market segment (capacity specified in the presentation).

The pharmaceutical market of Ukraine was 4 046 857 440 USD in 2019, 4 236 832 110 USD in 2020. And by results of the two quarters of 2021 shows growing dynamics (Q1+Q2 is 2 330 010 170 USD).

Solution (product or service)

More information about the products - in the presentation.
The portfolio includes 14 products (12 in active promotion, 2 in development), which are used in the following therapeutic areas: cardiology, neurology, gastroenterology, paediatrics, dermatology, traumatology, gynaecology, urology, andrology, cosmetology, dentistry. Also on the market are 8 products of our partners (full potential of the portfolio - 52 positions).

Competitors

The main competitors are the TOP-50 companies of the pharmaceutical market of Ukraine (TOP-20 in the dietary supplement segment).

Advantages or differentiators

Six of the twelve main products have unique differences and have no direct complete analogues at market.

Finance

The cost of products and sales forecasts - in the presentation.

At the moment our sales 350 000 USD per annum with only 2 regions, covering less than 7% of the total market. Our goal is to reach 3 000 000 USD sales in 2023 (1% of our market segment) and 9 000 000 USD in 2030 (3.2% of our market segment).

The first goal will be achievable when we will have representatives in each region (100% coverage of the market). And the second one we will achieve after portfolio expansion (+20 products). And the next step will be the export of products to other countries.

Business model

Sales channels - national pharmaceutical distributors, national and local pharmacy chains.
We currently have contracts with all major national pharmaceutical distributors, and our products are in the TOP-20 networks of Ukraine.

Reason for sale

2 co-owners need cash-out

Market

Markets and trands information - in presentation.

The volume of our current segment (our 12 active products) is 281 422 153 USD and will grow next 4 years (approx. +20% per year).

When we will expand our portfolio with 20 more products the market volume of our segment will be approx. 500 000 000 USD.

Team or Management

5,00
1
2
3
4
5
1 voice
Sign in/Sign up
arrow_back
EN
more_horiz
close
visibility982
star1
Add to favorites
Delete from favorites
share
close
thumb_up0
Like
Unlike
Does the enterprise work?
Idea
Current Status
Annual sales, $
Annual net income, $
Type of property
Property and assets
Organizational form
Number of employees
Problem or Opportunity
Solution (product or service)
Competitors
Advantages or differentiators
Finance
Business model
Reason for sale
Market
Team or Management
Risks
Invention/Patent
Product Video